Madrigal Pharmaceuticals Strategy and Business Model

Executive Overview

Madrigal is a U.S. biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH, the updated nomenclature for what many public filings still call nonalcoholic steatohepatitis (NASH). Headquartered in West Conshohocken, Pennsylvania, and founded in 2011, Madrigal spent more than a decade building a single lead asset, resmetirom, into a commercial product. In March 2024, the U.S. Food and Drug Administration granted accelerated approval to Rezdiffra, Madrigal’s brand name for resmetirom, for adults with noncirrhotic NASH with moderate to advanced liver fibrosis, consistent with stages F2 to F3, to be used with diet and exercise. That approval transformed Madrigal from a clinical-stage, pre-revenue biotech into a commercial specialty-pharma company. Through FY2023, Madrigal had no product revenue; 2024 marked the start of commercial sales. Strategically, Madrigal is highly concentrated: one core disease area, one marketed product, one primary launch geography, and a commercial model built around specialist prescribers, payer access, patient identification, and continued evidence generation. The company’s upside is substantial if it can turn first-mover status into durable category leadership, but its operating model also carries classic single-product biotech execution risk.

Madrigal at a Glance

Logo
Common name	Madrigal
Full legal name	Madrigal Pharmaceuticals, Inc.
Headquarters	West Conshohocken, Pennsylvania, United States
Ownership	Public company; Nasdaq-listed. No controlling shareholder was publicly disclosed in recent filings reviewed.
Ticker	MDGL
Exchange	NASDAQ
Market Cap	$11.78B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Private Madrigal was formed in 2011; the company became public through its 2016 merger with Synta Pharmaceuticals; Rezdiffra received U.S. FDA accelerated approval in 2024.
Industry or industries	Biopharmaceuticals; hepatology; metabolic disease
Key products or services	Rezdiffra (resmetirom), an oral thyroid hormone receptor-beta agonist for eligible adults with noncirrhotic NASH/MASH with F2-F3 fibrosis; related clinical development and medical affairs activities
Geographic footprint	Commercial focus in the United States as of 2024; clinical development and outsourced operations span additional countries through trial sites and vendor partners
Business segments as officially reported	One operating and reportable segment
Company website	https://www.madrigalpharma.com/

1. What Is the Strategy of Madrigal?

1. 1a. What is the winning aspiration of Madrigal?

   Madrigal’s public strategy in 2024 points to a focused aspiration: become the leading company in MASH by turning Rezdiffra into the foundational therapy for eligible patients and then broadening the franchise through additional evidence, additional patient populations, and broader adoption. This is not a diversified big-pharma ambition. Madrigal is trying to win in a specific disease category where there was no previously approved U.S. therapy.

   In practical terms, winning means three things. First, execute the U.S. launch well enough to establish Rezdiffra as the reference product in noncirrhotic disease with F2-F3 fibrosis. Second, satisfy the post-approval evidence burden that comes with accelerated approval. Third, convert a single approval into a durable liver-disease franchise rather than a one-time launch event.

2. 1b. Where does Madrigal play?

   Madrigal plays in specialty biopharma, specifically liver disease and metabolic disease at the intersection of hepatology, gastroenterology, and selected endocrinology. Its current commercial focus, as of 2024, is adults in the United States with noncirrhotic NASH/MASH and moderate to advanced fibrosis. That is a narrower field than “all liver disease” or “all metabolic disease,” and it reflects a deliberate strategic choice.

   Madrigal’s near-term geographic playbook is also narrow. Revenue is U.S.-centered, with commercial resources directed at specialist prescribers and payer access in the United States. Beyond that, its development footprint extends into adjacent liver-disease populations through ongoing studies, including outcome-oriented work and compensated cirrhosis, but those remain development opportunities rather than broad commercial markets today.

3. 1c. How does Madrigal plan to win?

   Madrigal’s “how to win” has four parts. The first is first-mover advantage: Rezdiffra became the first FDA-approved treatment in the category in March 2024. The second is product profile: a once-daily oral therapy with clinical data in liver histology and favorable effects on certain atherogenic lipids, which gives physicians a tangible reason to prescribe rather than wait for future entrants. The third is focused commercialization: a specialist launch aimed at the physicians most likely to diagnose and treat eligible patients. The fourth is market creation: helping the healthcare system find patients in a disease area that has historically been underdiagnosed and operationally difficult to treat.

   That matters because MASH is not a market where demand automatically presents itself at the pharmacy counter. Madrigal has to support diagnosis pathways, referral flows, payer access, and physician confidence at the same time it promotes the product.

4. 1d. What capabilities must Madrigal have in place?

   Madrigal needs a mix of biotech and specialty-pharma capabilities. On the biotech side, it needs regulatory, clinical-development, pharmacovigilance, and medical-affairs strength to support an accelerated-approval product and continue label-supporting development. On the commercial side, it needs a targeted field force, payer and reimbursement expertise, patient support infrastructure, health-economics and outcomes communication, and launch analytics.

   It also needs capabilities that are easy to underappreciate but strategically critical for a single-product company: quality oversight of contract manufacturers, demand forecasting, inventory management, and disciplined vendor management. Because Madrigal outsources much of its manufacturing and operational infrastructure, execution depends heavily on how well it orchestrates external partners.

5. 1e. What management systems does Madrigal require?

   Madrigal needs management systems that connect commercial execution to scientific evidence and regulatory compliance. That includes launch dashboards for prescription trends, payer coverage, time to therapy, abandonment rates, and physician targeting; formal quality and supply systems for outsourced manufacturing; and safety-monitoring and reporting systems consistent with post-approval obligations.

   It also needs disciplined capital-allocation and scenario-planning processes. A company with one marketed asset can create significant value quickly, but it can also overbuild ahead of demand. The right management system for Madrigal is therefore one that links spend, headcount, inventory, and development priorities to real launch signals rather than to optimism alone.

2. What Are the Current Strategic Initiatives of Madrigal?

• Commercializing Rezdiffra in the United States. Since the March 2024 FDA approval, Madrigal’s central initiative has been the U.S. launch of Rezdiffra. That includes building awareness among hepatologists, gastroenterologists, and selected endocrinologists; securing formulary access; supporting prior authorization; and converting initial demand into repeat prescribing.

• Expanding patient identification in an underdiagnosed disease. MASH is not a category where all eligible patients are already in specialist care. Public company materials in 2024 emphasized education around fibrosis staging, non-invasive tests, referral patterns, and specialist workflows. This is strategically important because patient finding is part of market creation, not just marketing.

• Executing the post-approval evidence agenda. Rezdiffra’s approval in 2024 was an accelerated approval. That means Madrigal must continue generating evidence to verify clinical benefit and support broader physician and payer confidence. Ongoing studies and long-term follow-up are therefore part of the commercial strategy, not separate from it.

• Extending the franchise beyond the initial label. Madrigal has publicly discussed additional development opportunities for resmetirom, including outcome-oriented work and compensated MASH cirrhosis. The logic is straightforward: if the molecule can prove value in broader or more advanced disease, the commercial franchise becomes more durable.

• Scaling technical operations and supply reliability. A successful launch requires more than demand generation. Madrigal must maintain commercial inventory, quality oversight, packaging, distribution, and reimbursement support without the manufacturing redundancy of a large pharma company. For a single-product company, supply continuity is a strategic initiative in its own right.

3. What Is the Business Model of Madrigal?

What customers actually buy

Madrigal now sells a branded prescription medicine: Rezdiffra. Immediate commercial customers are the specialty channel participants that buy and distribute the product, while economic decision-makers include commercial payers, pharmacy benefit managers, and health systems. Physicians prescribe it, patients use it, and payers determine much of the real-world access.

What portion of the model appears recurring or repeat-driven versus one-time

The model is primarily recurring. Rezdiffra is intended as a chronic therapy for eligible patients, so value depends less on a one-time course of treatment and more on patient starts, refill persistence, adherence, and duration on therapy. That makes the business more repeat-driven than a typical one-time procedure company, but real recurrence will depend on access, tolerability, and physician confidence.

How pricing power works, if at all

As the first approved therapy in its category in 2024, Madrigal appears to have some initial pricing leverage. But in biopharma, list-price power is only part of the story. Realized pricing depends on rebates, gross-to-net deductions, coverage criteria, and competitive dynamics as new therapies emerge. In other words, first-mover status helps, but payer discipline still matters.

Why the business mix matters

Madrigal’s business mix is unusually concentrated. As of 2024, it is essentially a one-product, one-core-indication, one-main-geography company. That concentration can create strong operating leverage if Rezdiffra adoption scales, but it also means the company does not have a diversified portfolio to cushion reimbursement setbacks, safety surprises, slower-than-expected diagnosis rates, or competitive entry.

What drives gross margin, operating margin, and cash generation

At scale, gross margin should look more like specialty pharma than like a low-margin manufacturing business because Rezdiffra is an oral small-molecule medicine and Madrigal outsources much of production. The bigger near-term drivers of operating margin are commercial buildout, medical affairs, and continued research and development rather than cost of goods alone. Cash generation will depend on the pace of prescription uptake, working-capital discipline, gross-to-net management, and how long Madrigal continues to invest heavily in lifecycle studies and launch support.

Revenue model

The revenue model is a traditional prescription-drug model rather than subscription, rental, or fee-for-service. Revenue is recognized on product sales through the commercial channel, net of typical pharmaceutical deductions such as rebates, chargebacks, and returns. Before 2024, Madrigal was essentially a development-stage, pre-revenue company; after approval, it became a commercial biopharma company.

4. What Products and/or Services Does Madrigal Sell?

As of 2024, Madrigal is effectively a one-product company.

• Rezdiffra (resmetirom). Rezdiffra is Madrigal’s only marketed product and its most important asset by a wide margin. In March 2024, the FDA granted accelerated approval for adults with noncirrhotic NASH with moderate to advanced liver fibrosis, consistent with stages F2 to F3, with diet and exercise. It is a once-daily oral therapy and the company’s entire commercial story currently rests on it.

• Resmetirom lifecycle development. Madrigal does not separately “sell” its development programs, but they are strategically central. Ongoing and planned studies are designed to verify benefit after accelerated approval, support physician confidence, and explore additional patient populations such as more advanced liver disease.

Madrigal does not have a legacy portfolio, broad service line, or multiple established brands. That makes the company easier to understand than a diversified pharma company, but it also means nearly all revenue, value creation, and strategic risk are tied to one molecule.

5. What Are the Key Competitors or Peers of Madrigal?

As of Rezdiffra’s March 2024 approval, Madrigal had no direct approved U.S. competitor in MASH. The most relevant competitive set therefore includes late-stage pipeline companies, adjacent metabolic-disease players, and historical NASH peers.

• Akero Therapeutics. Akero is one of the closest pure-play MASH peers, developing efruxifermin, an FGF21 analog, in late-stage studies. It is a direct pipeline competitor for specialist attention, capital, and future MASH share.

• 89bio. 89bio is another prominent MASH-focused peer, developing pegozafermin, also based on FGF21 biology. Like Akero, it represents future direct competition if clinical and regulatory progress continues.

• Viking Therapeutics. Viking’s VK2809 is particularly relevant because it is also a thyroid hormone receptor-beta agonist. That makes Viking a close mechanism-level peer for investors and a potential future commercial competitor.

• Novo Nordisk. Novo is not a pure MASH competitor in the same narrow sense, but its obesity and diabetes franchise gives it major influence over the metabolic-disease treatment landscape. Its programs in liver disease and the broader use of GLP-1-based therapy make it an important adjacent competitor and possible future standard-of-care shaper.

• Eli Lilly. Like Novo, Lilly matters because metabolic and obesity therapies can affect how physicians treat the same patient population. Even when not directly labeled for MASH, these therapies can act as substitutes, complements, or sequencing competitors.

• Boehringer Ingelheim and Zealand Pharma. Their glucagon/GLP-1-based program survodutide has made them relevant participants in the broader MASH pipeline. This is another example of adjacent metabolic players moving into Madrigal’s target field.

• Gilead Sciences. Gilead has long pursued liver-disease and MASH opportunities and remains a closely watched peer in terms of scientific and strategic interest, even though it did not have an approved MASH product in the U.S. as of 2024.

• Intercept Pharmaceuticals / Alfasigma. Intercept was the most visible historical NASH peer before Rezdiffra’s approval, though obeticholic acid did not secure U.S. approval for that indication. It remains relevant as a reference point for the category’s regulatory history.

The broader point is that Madrigal’s competition comes from two directions: direct MASH entrants and large metabolic-disease companies whose products can influence the same physician and patient economics.

6. What Is the Marketing Strategy of Madrigal?

Madrigal’s marketing strategy is best understood as specialist category creation rather than mass-market pharmaceutical advertising. In 2024, the company’s task was not simply to promote a brand name. It had to educate the market on which patients are eligible, how to identify fibrosis stage, how to navigate treatment initiation, and why Rezdiffra should be used now rather than after additional competitive entry.

That implies a mix of field promotion, medical education, key-opinion-leader engagement, payer communication, and patient-support messaging. Brand marketing matters, but disease-state marketing and evidence-based education likely matter more. In a new category, the commercial question is often “who is the patient and how do I find them?” before it becomes “which brand do I pick?”

Madrigal’s marketing model therefore appears to be heavily specialist-focused, with account-level and field-based execution more important than consumer advertising. Marketing is a differentiator to the extent that it helps build the diagnosis funnel and reduce friction between specialist awareness and actual treatment starts.

7. What Are the Key Customer Segments of Madrigal?

• Specialist prescribers. The most important physician segments are hepatologists and gastroenterologists, with selected endocrinologists also relevant because MASH overlaps with obesity, diabetes, and broader metabolic disease. These specialists determine adoption in the early years.

• Adult patients with noncirrhotic MASH/NASH and F2-F3 fibrosis. This is the core end-market population under the initial U.S. label as of 2024. Madrigal is not serving a broad primary-care population at launch; it is serving a narrower, higher-acuity specialty population.

• Payers and pharmacy benefit managers. These are not “customers” in the classic consumer sense, but they are decisive gatekeepers. Coverage criteria, step edits, prior authorization rules, and net pricing can shape real demand as much as physician interest.

• Specialty distributors and specialty pharmacies. These are the direct commercial channel partners through which product moves to patients. Their operational role is important because they influence speed to therapy, refill logistics, and patient onboarding.

• Health systems and referral networks. Large liver centers, integrated delivery systems, and networks that manage diagnosis and referral patterns also matter, especially in an underdiagnosed disease where care pathways are still forming.

Madrigal is therefore not broadly diversified by customer type. Its early commercial success depends heavily on a relatively concentrated specialist ecosystem.

8. What Is the Sales Model of Madrigal?

Madrigal’s sales model is a classic specialty-pharma model. The company uses a dedicated field force to call on targeted specialists, while product distribution runs through specialty channels rather than broad retail saturation. That keeps the model focused on high-value prescribers and the operational steps needed to convert a prescription into a paid therapy start.

• Direct physician selling. Madrigal’s commercial team engages the specialists most likely to diagnose and manage eligible patients.

• Market access and reimbursement support. Because payer approval is critical, sales success depends on payer contracting, prior-authorization support, and patient-support services, not just detailing.

• Specialty distribution and pharmacy. This channel structure helps manage product flow, data visibility, and patient onboarding in a more controlled way than a fully open retail model would.

• Medical-affairs overlay. In a new disease category, scientific exchange and medical education are tightly linked to sales effectiveness.

This channel structure gives Madrigal relatively high customer intimacy with prescribers and accounts, but it also means growth depends on field-force productivity, access workflows, and patient-services execution. For consultants, that makes territory design, launch analytics, reimbursement operations, and hub optimization especially relevant.

9. In What Geographies Does Madrigal Operate?

As of 2024, Madrigal’s operating footprint is U.S.-centric. Its headquarters is in West Conshohocken, Pennsylvania, and its commercial effort is focused on the United States because Rezdiffra’s initial approval and launch are U.S.-based. Field sales, medical, and market-access activities are therefore oriented around U.S. specialists, U.S. payers, and U.S. patient-support processes.

Its broader operating footprint is wider than its revenue footprint. Like many biopharma companies, Madrigal relies on third-party manufacturers, clinical-trial partners, laboratories, and other vendors that can be based in multiple countries. Its clinical-development activities have involved a broader site network than its commercial footprint suggests. Even so, near-term revenue concentration is clearly in the United States rather than in a globally diversified commercial base.

10. Who Are the Owners of Madrigal?

Madrigal is a publicly traded company. As of public ownership disclosures around early 2024, the shareholder base was primarily institutional, with large holders including specialist biotech investors and broad asset managers. Public filings have included firms such as Baker Bros. Advisors, The Vanguard Group, and BlackRock among notable holders, although ownership percentages can change materially over time. No controlling shareholder was publicly disclosed in the materials reviewed.

11. How Is Madrigal Organized?

Madrigal reports one operating and reportable segment, which is typical for a focused biotech with a single lead franchise. Practically, the company appears organized around functions rather than around multiple business units or geographies.

• Commercial. Sales, marketing, commercial operations, market access, and patient services supporting the Rezdiffra launch.

• Research, development, and medical. Clinical development, regulatory affairs, medical affairs, pharmacovigilance, and evidence generation.

• Technical operations. Chemistry, manufacturing, and controls; supply chain; quality; and oversight of external manufacturing partners.

• Corporate functions. Finance, legal, human resources, investor relations, and general administration.

There is no sign of a complex holding-company model, major autonomous divisions, or a large multi-brand portfolio structure. The organizational challenge is not complexity of structure; it is balancing commercialization and continued development around the same asset.

12. How Does Madrigal Operate?

Madrigal operates as a focused biopharma company that combines internal strategic control with heavy use of external partners. Day to day, the company creates value through a set of linked activities:

1. Generate and interpret clinical evidence. The company runs studies, manages regulatory interactions, supports medical education, and maintains the evidence base around resmetirom.

2. Oversee outsourced manufacturing and quality. Rather than running a large internal manufacturing network, Madrigal manages contract partners for drug substance, drug product, packaging, release, and supply continuity.

3. Create commercial demand. The field organization engages specialists, communicates the clinical profile, and helps the market understand which patients are eligible.

4. Navigate access and patient onboarding. Prescriptions must move through payer review, prior authorization, specialty pharmacy workflows, and patient-support processes.

5. Monitor safety and product performance. As a newly launched medicine, Rezdiffra requires pharmacovigilance, post-marketing oversight, and continuous operating feedback.

The main operational bottlenecks are likely patient identification, reimbursement friction, supply reliability, and the challenge of running commercial and development workstreams simultaneously. Because Madrigal is so concentrated, small operational misses can have outsized financial consequences.

13. What Are the Growth Opportunities for Madrigal?

• Deeper penetration of the currently labeled U.S. population. The first and most obvious opportunity is simply to identify and treat more eligible F2-F3 patients in the United States. In many ways, this is the largest near-term opportunity because MASH remains underdiagnosed.

• Improved diagnosis and referral economics. If non-invasive testing, fibrosis staging, and referral patterns improve, Madrigal’s addressable treated population can expand without any label change. This is as much a healthcare-system execution opportunity as a pure demand-generation opportunity.

• Additional clinical evidence and broader physician confidence. More long-term data can strengthen adoption, reduce payer hesitation, and support use earlier in the physician decision process. Real-world evidence can matter here almost as much as promotional spend.

• Label expansion into additional populations. Publicly discussed development in more advanced disease, including compensated cirrhosis, is a meaningful growth avenue if the data support it and regulators approve it. This is one of the most important medium-term opportunities.

• Ex-U.S. expansion. International commercialization could become important over time, whether through Madrigal’s own buildout or through partnerships. As of 2024, however, this is more a future lever than a fully developed revenue engine.

• Combination and broader metabolic-care positioning. A reasonable external inference is that the long-term MASH market may involve combination or sequenced therapy with obesity and diabetes agents. If Madrigal can position Rezdiffra well within that broader care pathway, it may improve durability against larger metabolic competitors.

The main constraints are also clear: single-product concentration, the need to verify clinical benefit after accelerated approval, payer controls, competitive pipeline entry, and the practical challenge of finding eligible patients consistently.

14. What Is the History of Madrigal?

Madrigal’s current public-company history is best understood as the combination of a private biotech story and a public-company merger story.

• 2011: Private Madrigal Pharmaceuticals was formed to develop therapies for metabolic and liver disease, with resmetirom becoming its defining asset.

• 2016: Private Madrigal merged with Synta Pharmaceuticals, a public biotech company. The combined company adopted the Madrigal name and continued as a Nasdaq-listed business. This merger effectively created the current public-company platform.

• 2018: Positive Phase 2 data for MGL-3196, later named resmetirom, helped put Madrigal on the map as one of the more serious NASH contenders.

• 2022-2023: Phase 3 MAESTRO-NASH data and the subsequent regulatory process moved the company from promise toward commercial reality.

• 2024: The FDA granted accelerated approval to Rezdiffra, making it the first approved U.S. therapy for the indication and turning Madrigal into a commercial company.

Public materials tend to emphasize the development arc of resmetirom and the 2016 Synta transaction more than a single-founder narrative. The strategically important historical fact is that Madrigal spent years as a highly focused development-stage biotech and then crossed into commercialization with one category-defining approval.

15. What Are the Key Suppliers to Madrigal?

Suppliers matter meaningfully to Madrigal because the company depends on third parties for much of its manufacturing and operating infrastructure. Madrigal does not publicly emphasize a long list of named suppliers in the way a heavy industrial company might, but its filings make clear that external partners are essential.

• Contract manufacturing organizations. These partners produce active pharmaceutical ingredient, finished drug product, and related manufacturing steps.

• Packaging, labeling, and logistics vendors. These suppliers support commercial readiness, inventory flow, and compliant delivery into the specialty channel.

• Specialty distributors and specialty pharmacies. They are channel partners rather than classic raw-material suppliers, but they are critical to getting product to patients.

• Clinical research organizations, laboratories, and site-management partners. These vendors matter for ongoing studies, biomarker work, and long-term evidence generation.

• Technology and service providers. Pharmacovigilance, patient-support platforms, customer-relationship systems, and reimbursement-support vendors also matter materially.

Supplier structure is strategically important because Madrigal does not have the internal redundancy of a global pharma major. For a one-product company, a manufacturing or service interruption can affect both revenue and reputation very quickly.

16. How Does the Supply Chain of Madrigal Function?

Madrigal’s supply chain is simpler than that of a biologics company or a cell-therapy company, but it is still strategically important. Rezdiffra is an oral small-molecule medicine, so the supply chain typically runs from active ingredient production to finished-dose manufacturing, quality testing, packaging and labeling, inventory management, distribution into specialty channels, and then dispensing to patients through specialty-pharmacy workflows.

The high-stakes issues are less about cold-chain complexity and more about forecasting, regulatory compliance, vendor reliability, and commercial responsiveness. A new launch can create demand volatility; too little inventory risks stock-outs, while too much can tie up cash. Because payer approval and patient onboarding are part of the delivery process, Madrigal’s commercial supply chain is intertwined with reimbursement operations and patient support rather than ending at a wholesaler dock.

17. What Is the R&D Strategy of Madrigal?

Madrigal’s R&D strategy remains central even after commercialization. In 2024, the company was not transitioning out of research so much as shifting from a single approval event to a franchise-building evidence agenda. That agenda includes verifying clinical benefit after accelerated approval, building long-term safety and outcomes evidence, and exploring additional disease stages such as compensated MASH cirrhosis.

This is a concentrated R&D model. Rather than spreading resources across a large early-stage pipeline, Madrigal’s value creation is heavily centered on deepening and expanding the resmetirom franchise. That can be a strength because it keeps organizational focus high, but it also means the R&D portfolio is less diversified than that of a larger biotech or pharma company.

In practical terms, Madrigal’s R&D spending supports three goals: regulatory durability, physician confidence, and future label breadth. For this company, research is not separate from commercialization; it is one of the main supports for commercialization.

18. What Is the Finance Strategy of Madrigal?

Madrigal’s finance strategy, as of 2024, is shaped by the transition from a development-stage biotech to a commercial one-product company. The main capital-allocation priorities are clear: fund the Rezdiffra launch, maintain balance-sheet flexibility, invest in post-approval and lifecycle studies, support manufacturing scale-up, and preserve enough liquidity to manage launch volatility.

Historically, Madrigal relied on capital markets rather than internally generated cash flow. That is normal for a biotech before first product approval. As commercialization begins, the financial model changes: inventory, gross-to-net deductions, accounts receivable, and operating leverage start to matter more than they did in a pure R&D phase. Even so, near-term profitability is likely to be shaped more by commercial and development investment levels than by manufacturing cost alone.

Madrigal is not a dividend or buyback story. Its finance strategy is about disciplined reinvestment, cash runway management, and avoiding the twin risks of underfunding a category-defining launch or overspending before demand is fully proven.

19. How Companies Like Madrigal Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Madrigal use Umbrex when they need the training and rigor of top-tier consulting talent but do not need a full consulting team with all the overhead. For a focused biopharma company, the best use cases are narrow, high-impact projects tied directly to launch execution, operating leverage, evidence strategy, and organizational scaling.

• MASH patient-finding strategy. Map referral flows, non-invasive testing adoption, and center-level patient-identification bottlenecks to increase the pool of eligible F2-F3 patients.

• Launch diagnostic and commercial performance review. Assess territory design, call-point prioritization, sales-force productivity, and launch conversion from prescriber intent to actual therapy starts.

• Payer access and gross-to-net optimization. Review coverage strategy, payer segmentation, contracting scenarios, and hub performance to improve net realization and speed to therapy.

• Patient-support operating model redesign. Improve prior-authorization workflows, specialty-pharmacy handoffs, abandonment reduction, and refill persistence.

• Specialty-channel strategy. Evaluate distributor and specialty-pharmacy structure, service-level agreements, data visibility, and channel economics for a single-product launch.

• Commercial supply-chain and S&OP buildout. Create better demand forecasting, inventory policy, vendor-risk management, and supply-continuity planning for Rezdiffra.

• Lifecycle strategy and indication prioritization. Build strategic and financial cases for additional studies, outcomes evidence, cirrhosis opportunities, and combination or sequencing options.

• International market-entry planning. Assess where Madrigal should build directly, where it should partner, and how reimbursement and specialist dynamics differ across major ex-U.S. markets.

• Commercial analytics and forecasting. Develop launch dashboards, patient-flow models, payer-access analytics, and scenario plans for board and investor communication.

• Organization and PMO support. Stand up a commercialization-and-development program office to coordinate medical, market access, supply, finance, and field execution around one critical asset.